Home ➤ Life Science ➤ Pharmaceuticals ➤ HIV Drugs Market
HIV Drugs Market
Published date: June 2025 • Formats:
Request Sample Schedule a Call

HIV Drugs Market By Product Type (Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry and Fusion Inhibitors, and Combination Class Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

  • Published date: June 2025
  • Report ID: 151718
  • Number of Pages: 337
  • Format:
  • keyboard_arrow_up
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Market Snapshot
      • 1.3. Market Overview
      • 1.4. Segment Overview
      • 1.5. Regional Overview
      • 1.6. Competitive Landscape
      • 1.7. Taxonomy
      • 1.8. Industry Voices
    • 2. Global Market Overview
      • 2.1. Global Market Insights and Industry Overview
      • 2.2. Market Dynamics
        • 2.2.1. Drivers
        • 2.2.2. Restraints
        • 2.2.3. Opportunities
        • 2.2.4. Key HIV Drugs Market Trends
      • 2.3. Technology Landscape
      • 2.4. Regulatory Framework
      • 2.5. Sustainability and ESG (Environmental, Social, Governance)
      • 2.6. Opportunity Map Analysis
      • 2.7. Opportunity Orbits
      • 2.8. PESTLE Analysis
      • 2.9. PORTER’S Five Force Analysis
      • 2.10. Drivers & Restraints Impact Analysis
      • 2.11. Value Chain Analysis
        • 2.11.1. List of Raw Materials Suppliers
        • 2.11.2. List of HIV Drugs Manufacturers
        • 2.11.3. List of Dealer/Distributors
      • 2.12. Regional Market Share and BPS Analysis
      • 2.13. Impact of Macro-economic Factors/Geopolitical Factors
    • 3. Global HIV Drugs Market Analysis and Forecast, By Segment, 2020-2034
      • 3.1. Key Findings
      • 3.2. Global HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 3.3. Global HIV Drugs Market Attractiveness Analysis, By Product Type
        • 3.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          • 3.3.1.1. Insights
          • 3.3.1.2. Key Takeaways
        • 3.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
          • 3.3.2.1. Insights
          • 3.3.2.2. Key Takeaways
        • 3.3.3. Protease Inhibitors (PIs)
          • 3.3.3.1. Insights
          • 3.3.3.2. Key Takeaways
        • 3.3.4. Integrase Inhibitors
          • 3.3.4.1. Insights
          • 3.3.4.2. Key Takeaways
        • 3.3.5. Entry and Fusion Inhibitors
          • 3.3.5.1. Insights
          • 3.3.5.2. Key Takeaways
        • 3.3.6. Combination Class Drugs
          • 3.3.6.1. Insights
          • 3.3.6.2. Key Takeaways
      • 3.4. Global HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 3.5. Global HIV Drugs Market Attractiveness Analysis, By Distribution Channel
        • 3.5.1. Hospital Pharmacies
          • 3.5.1.1. Insights
          • 3.5.1.2. Key Takeaways
        • 3.5.2. Retail Pharmacies
          • 3.5.2.1. Insights
          • 3.5.2.2. Key Takeaways
        • 3.5.3. Online Pharmacies
          • 3.5.3.1. Insights
          • 3.5.3.2. Key Takeaways
    • 4. Global HIV Drugs Market Analysis and Forecast, By Region, 2020-2034
      • 4.1. Key Findings
      • 4.2. Global HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
        • 4.2.1. North America
          • 4.2.1.1. Regional Insights
        • 4.2.2. Europe
          • 4.2.2.1. Regional Insights
        • 4.2.3. Asia Pacific
          • 4.2.3.1. Regional Insights
        • 4.2.4. Latin America
          • 4.2.4.1. Regional Insights
        • 4.2.5. Middle East & Africa
          • 4.2.5.1. Regional Insights
      • 4.3. Global HIV Drugs Market Attractiveness Analysis, By Region
    • 5. North America HIV Drugs Market Analysis and Forecast, 2020-2034
      • 5.1. Key Findings
      • 5.2. North America HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 5.3. North America HIV Drugs Market Attractiveness Analysis, By Product Type
      • 5.4. North America HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 5.5. North America HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • 5.6. North America HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 5.7. North America HIV Drugs Market Attractiveness Analysis, By Country
        • 5.7.1. The US
        • 5.7.2. Canada
    • 6. Europe HIV Drugs Market Analysis and Forecast, 2020-2034
      • 6.1. Key Findings
      • 6.2. Europe HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 6.3. Europe HIV Drugs Market Attractiveness Analysis, By Product Type
      • 6.4. Europe HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 6.5. Europe HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • 6.6. Europe HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 6.7. Europe HIV Drugs Market Attractiveness Analysis, By Country
        • 6.7.1. Germany
        • 6.7.2. The UK
        • 6.7.3. France
        • 6.7.4. Spain
        • 6.7.5. Italy
        • 6.7.6. Russia
        • 6.7.7. Netherland
        • 6.7.8. Rest of Europe
    • 7. Asia Pacific HIV Drugs Market Analysis and Forecast, 2020-2034
      • 7.1. Key Findings
      • 7.2. Asia Pacific HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 7.3. Asia Pacific HIV Drugs Market Attractiveness Analysis, By Product Type
      • 7.4. Asia Pacific HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 7.5. Asia Pacific HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • 7.6. Asia Pacific HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 7.7. Asia Pacific HIV Drugs Market Attractiveness Analysis, By Country
        • 7.7.1. China
        • 7.7.2. Japan
        • 7.7.3. South Korea
        • 7.7.4. India
        • 7.7.5. Australia
        • 7.7.6. New Zealand
        • 7.7.7. Singapore
        • 7.7.8. Thailand
        • 7.7.9. Vietnam
        • 7.7.10. Rest of Asia Pacific
    • 8. Latin America HIV Drugs Market Analysis and Forecast, 2020-2034
      • 8.1. Key Findings
      • 8.2. Latin America HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 8.3. Latin America HIV Drugs Market Attractiveness Analysis, By Product Type
      • 8.4. Latin America HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 8.5. Latin America HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • 8.6. Latin America HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 8.7. Latin America HIV Drugs Market Attractiveness Analysis, By Country
        • 8.7.1. Brazil
        • 8.7.2. Mexico
        • 8.7.3. Rest of Latin America
    • 9. Middle East & Africa HIV Drugs Market Analysis and Forecast, 2020-2034
      • 9.1. Key Findings
      • 9.2. Middle East & Africa HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 9.3. Middle East & Africa HIV Drugs Market Attractiveness Analysis, By Product Type
      • 9.4. Middle East & Africa HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
      • 9.5. Middle East & Africa HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • 9.6. Middle East & Africa HIV Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 9.7. Middle East & Africa HIV Drugs Market Attractiveness Analysis, By Country
        • 9.7.1. South Africa
        • 9.7.2. Saudi Arabia
        • 9.7.3. UAE
        • 9.7.4. Rest of Middle East & Africa
    • 10. Competitive Landscape & Company Profiles
      • 10.1. Market Competition Scenario Analysis, By Company
        • 10.1.1. Key Takeaways
      • 10.2. Overview of Major Market Players
      • 10.3. Competitor Landscape
      • 10.4. Strategic Mapping
      • 10.5. Company Life Cycle Analysis
      • 10.6. Company Market Share Analysis
      • 10.7. Company Profiles
        • 10.7.1. ViiV Healthcare
          • 10.7.1.1. Company Details
          • 10.7.1.2. Business Overview
          • 10.7.1.3. Product Portfolio
          • 10.7.1.4. Financial Insights
          • 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.1.6. SWOT Analysis
          • 10.7.1.7. Geographic Footprint
        • 10.7.2. Theratechnologies Inc
          • 10.7.2.1. Company Details
          • 10.7.2.2. Business Overview
          • 10.7.2.3. Product Portfolio
          • 10.7.2.4. Financial Insights
          • 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.2.6. SWOT Analysis
          • 10.7.2.7. Geographic Footprint
        • 10.7.3. Mylan Pharmaceuticals Inc
          • 10.7.3.1. Company Details
          • 10.7.3.2. Business Overview
          • 10.7.3.3. Product Portfolio
          • 10.7.3.4. Financial Insights
          • 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.3.6. SWOT Analysis
          • 10.7.3.7. Geographic Footprint
        • 10.7.4. Gilead Sciences, Inc
          • 10.7.4.1. Company Details
          • 10.7.4.2. Business Overview
          • 10.7.4.3. Product Portfolio
          • 10.7.4.4. Financial Insights
          • 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.4.6. SWOT Analysis
          • 10.7.4.7. Geographic Footprint
        • 10.7.5. F. Hoffmann-La Roche Ltd
          • 10.7.5.1. Company Details
          • 10.7.5.2. Business Overview
          • 10.7.5.3. Product Portfolio
          • 10.7.5.4. Financial Insights
          • 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.5.6. SWOT Analysis
          • 10.7.5.7. Geographic Footprint
        • 10.7.6. Cipla Ltd
          • 10.7.6.1. Company Details
          • 10.7.6.2. Business Overview
          • 10.7.6.3. Product Portfolio
          • 10.7.6.4. Financial Insights
          • 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.6.6. SWOT Analysis
          • 10.7.6.7. Geographic Footprint
        • 10.7.7. Boehringer Ingelheim International GmbH
          • 10.7.7.1. Company Details
          • 10.7.7.2. Business Overview
          • 10.7.7.3. Product Portfolio
          • 10.7.7.4. Financial Insights
          • 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.7.6. SWOT Analysis
          • 10.7.7.7. Geographic Footprint
        • 10.7.8. AbbVie
          • 10.7.8.1. Company Details
          • 10.7.8.2. Business Overview
          • 10.7.8.3. Product Portfolio
          • 10.7.8.4. Financial Insights
          • 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.8.6. SWOT Analysis
          • 10.7.8.7. Geographic Footprint
    • 11. Methodology and Data Source
      • 11.1. Methodology/Research Approach
      • 11.2. Market Size Estimation
      • 11.3. Market Breakdown and Data Triangulation
      • 11.4. Data Source
      • 11.5. Secondary Sources
      • 11.6. Primary Sources
      • 11.7. Appendix
      • 11.8. Disclaimer
    • List of Tables
      • Table 1. Global HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 2. Global HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 3. Global HIV Drugs Market Value (US$ Mn), By Region, 2020-2034
      • Table 4. North America HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 5. North America HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 6. North America HIV Drugs Market Value (US$ Mn), By Country, 2020-2034
      • Table 7. The US HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 8. The US HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 9. Canada HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 10. Canada HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 11. Europe HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 12. Europe HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 13. Europe HIV Drugs Market Value (US$ Mn), By Country, 2020-2034
      • Table 14. Germany HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 15. Germany HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 16. The UK HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 17. The UK HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 18. France HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 19. France HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 20. Spain HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 21. Spain HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 22. Italy HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 23. Italy HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 24. Russia HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 25. Russia HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 26. Netherland HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 27. Netherland HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 28. Rest of Europe HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 29. Rest of Europe HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 30. Asia Pacific HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 31. Asia Pacific HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 32. Asia Pacific HIV Drugs Market Value (US$ Mn), By Country, 2020-2034
      • Table 33. China HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 34. China HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 35. India HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 36. India HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 37. Japan HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 38. Japan HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 39. South Korea HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 40. South Korea HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 41. Australia HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 42. Australia HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 43. New Zealand HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 44. New Zealand HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 45. Singapore HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 46. Singapore HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 47. Thailand HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 48. Thailand HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 49. Vietnam HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 50. Vietnam HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 51. Rest of Asia Pacific HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 52. Rest of Asia Pacific HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 53. Latin America HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 54. Latin America HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 55. Latin America HIV Drugs Market Value (US$ Mn), By Country, 2020-2034
      • Table 56. Brazil HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 57. Brazil HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 58. Mexico HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 59. Mexico HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 60. Rest of Latin America HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 61. Rest of Latin America HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 62. Middle East & Africa HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 63. Middle East & Africa HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 64. Middle East & Africa HIV Drugs Market Value (US$ Mn), By Country, 2020-2034
      • Table 65. South Africa HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 66. South Africa HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 67. Saudi Arabia HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 68. Saudi Arabia HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 69. UAE HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 70. UAE HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
      • Table 71. Rest of Middle East & Africa HIV Drugs Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 72. Rest of Middle East & Africa HIV Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
    • List of Figures
      • Figure 1. Global HIV Drugs Market Snapshot: Market Value (US$ Mn), 2020-2034
      • Figure 2. Opportunity Map
      • Figure 3. Opportunity Orbit
      • Figure 4. Regional Market Share and BPS Analysis in HIV Drugs Market
      • Figure 5. Global HIV Drugs Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 6. Global HIV Drugs Market Attractiveness Analysis, By Product Type
      • Figure 7. Global HIV Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 8. Global HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • Figure 9. Global HIV Drugs Market Analysis, By Region, 2020, 2024 and 2034
      • Figure 10. Global HIV Drugs Market Attractiveness Analysis, By Region
      • Figure 11. North America HIV Drugs Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 12. North America HIV Drugs Market Attractiveness Analysis, By Product Type
      • Figure 13. North America HIV Drugs Market (US$ Mn), by Nucleoside Reverse Transcriptase Inhibitors (NRTIs), 2020-2034
      • Figure 14. North America HIV Drugs Market (US$ Mn), by Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), 2020-2034
      • Figure 15. North America HIV Drugs Market (US$ Mn), by Protease Inhibitors (PIs), 2020-2034
      • Figure 16. North America HIV Drugs Market (US$ Mn), by Integrase Inhibitors, 2020-2034
      • Figure 17. North America HIV Drugs Market (US$ Mn), by Entry and Fusion Inhibitors, 2020-2034
      • Figure 18. North America HIV Drugs Market (US$ Mn), by Combination Class Drugs, 2020-2034
      • Figure 19. North America HIV Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 20. North America HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • Figure 21. North America HIV Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 22. North America HIV Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 23. North America HIV Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 24. North America HIV Drugs Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 25. North America HIV Drugs Market Attractiveness Analysis, By Country
      • Figure 26. Europe HIV Drugs Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 27. Europe HIV Drugs Market Attractiveness Analysis, By Product Type
      • Figure 28. Europe HIV Drugs Market (US$ Mn), by Nucleoside Reverse Transcriptase Inhibitors (NRTIs), 2020-2034
      • Figure 29. Europe HIV Drugs Market (US$ Mn), by Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), 2020-2034
      • Figure 30. Europe HIV Drugs Market (US$ Mn), by Protease Inhibitors (PIs), 2020-2034
      • Figure 31. Europe HIV Drugs Market (US$ Mn), by Integrase Inhibitors, 2020-2034
      • Figure 32. Europe HIV Drugs Market (US$ Mn), by Entry and Fusion Inhibitors, 2020-2034
      • Figure 33. Europe HIV Drugs Market (US$ Mn), by Combination Class Drugs, 2020-2034
      • Figure 34. Europe HIV Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 35. Europe HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • Figure 36. Europe HIV Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 37. Europe HIV Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 38. Europe HIV Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 39. Europe HIV Drugs Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 40. Europe HIV Drugs Market Attractiveness Analysis, By Country
      • Figure 41. Asia Pacific HIV Drugs Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 42. Asia Pacific HIV Drugs Market Attractiveness Analysis, By Product Type
      • Figure 43. Asia Pacific HIV Drugs Market (US$ Mn), by Nucleoside Reverse Transcriptase Inhibitors (NRTIs), 2020-2034
      • Figure 44. Asia Pacific HIV Drugs Market (US$ Mn), by Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), 2020-2034
      • Figure 45. Asia Pacific HIV Drugs Market (US$ Mn), by Protease Inhibitors (PIs), 2020-2034
      • Figure 46. Asia Pacific HIV Drugs Market (US$ Mn), by Integrase Inhibitors, 2020-2034
      • Figure 47. Asia Pacific HIV Drugs Market (US$ Mn), by Entry and Fusion Inhibitors, 2020-2034
      • Figure 48. Asia Pacific HIV Drugs Market (US$ Mn), by Combination Class Drugs, 2020-2034
      • Figure 49. Asia Pacific HIV Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 50. Asia Pacific HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • Figure 51. Asia Pacific HIV Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 52. Asia Pacific HIV Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 53. Asia Pacific HIV Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 54. Asia Pacific HIV Drugs Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 55. Asia Pacific HIV Drugs Market Attractiveness Analysis, By Country
      • Figure 56. Latin America HIV Drugs Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 57. Latin America HIV Drugs Market Attractiveness Analysis, By Product Type
      • Figure 58. Latin America HIV Drugs Market (US$ Mn), by Nucleoside Reverse Transcriptase Inhibitors (NRTIs), 2020-2034
      • Figure 59. Latin America HIV Drugs Market (US$ Mn), by Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), 2020-2034
      • Figure 60. Latin America HIV Drugs Market (US$ Mn), by Protease Inhibitors (PIs), 2020-2034
      • Figure 61. Latin America HIV Drugs Market (US$ Mn), by Integrase Inhibitors, 2020-2034
      • Figure 62. Latin America HIV Drugs Market (US$ Mn), by Entry and Fusion Inhibitors, 2020-2034
      • Figure 63. Latin America HIV Drugs Market (US$ Mn), by Combination Class Drugs, 2020-2034
      • Figure 64. Latin America HIV Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 65. Latin America HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • Figure 66. Latin America HIV Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 67. Latin America HIV Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 68. Latin America HIV Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 69. Latin America HIV Drugs Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 70. Latin America HIV Drugs Market Attractiveness Analysis, By Country
      • Figure 71. Middle East & Africa HIV Drugs Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 72. Middle East & Africa HIV Drugs Market Attractiveness Analysis, By Product Type
      • Figure 73. Middle East & Africa HIV Drugs Market (US$ Mn), by Nucleoside Reverse Transcriptase Inhibitors (NRTIs), 2020-2034
      • Figure 74. Middle East & Africa HIV Drugs Market (US$ Mn), by Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), 2020-2034
      • Figure 75. Middle East & Africa HIV Drugs Market (US$ Mn), by Protease Inhibitors (PIs), 2020-2034
      • Figure 76. Middle East & Africa HIV Drugs Market (US$ Mn), by Integrase Inhibitors, 2020-2034
      • Figure 77. Middle East & Africa HIV Drugs Market (US$ Mn), by Entry and Fusion Inhibitors, 2020-2034
      • Figure 78. Middle East & Africa HIV Drugs Market (US$ Mn), by Combination Class Drugs, 2020-2034
      • Figure 79. Middle East & Africa HIV Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
      • Figure 80. Middle East & Africa HIV Drugs Market Attractiveness Analysis, By Distribution Channel
      • Figure 81. Middle East & Africa HIV Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
      • Figure 82. Middle East & Africa HIV Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
      • Figure 83. Middle East & Africa HIV Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
      • Figure 84. Middle East & Africa HIV Drugs Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 85. Middle East & Africa HIV Drugs Market Attractiveness Analysis, By Country
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

HIV Drugs Market
  • 151718
  • June 2025
    • ★★★★★
      ★★★★★
    • (142)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
Find Help
Legal
Explore
Secured Payment Options
Secured Payment Options